Key result
Percutaneous ASD or PFO closure is linked to a ~5% arrhythmia incidence within four months.
Why the study?
Conduction and rhythm anomalies associated with percutaneous device closure of ASD or PFO have been reported but require further characterization in a large cohort.
Does percutaneous device closure of ASD or PFO increase the risk of arrhythmias and electrocardiographic changes?
Cohort (n=610)
No
Does percutaneous device closure of ASD or PFO increase the risk of arrhythmias and electrocardiographic changes?
Percutaneous device closure of ASD or PFO is associated with a low risk (5.2%) of clinically significant post-procedure arrhythmias, though changes in atrial conduction markers occur.
No takes yet. Share an insight, caveat, or question.
May warrant short-term arrhythmia monitoring after ASD/PFO closure; leaves open need for prospective studies to quantify excess risk.
Johnson et al. (2011) conducted a cohort in Atrial septal defect (ASD) and patent foramen ovale (PFO) (n=610). Percutaneous device closure of ASD or PFO was evaluated on Arrhythmias in the 4 months following device placement. Percutaneous device closure of ASD or PFO was associated with a 5.2% incidence of arrhythmias in the 4 months following placement, and a 0.3% incidence of clinically significant heart block.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: